SCHEMBL2980968

SCHEMBL2980968

CN1CCN(c2ccc(C(=O)Nc3cc(C(=O)Nc4cc(F)cc(N5CCOCC5)c4)ccc3Cl)cn2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 1/20 0.52
KCNQ2 O43526 1/20 0.52
MAPT P10636 4/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
BRAF P15056 3/20 0.50
RAB9A P51151 3/20 0.50
LMNA P02545 1/20 0.50
HTT P42858 1/20 0.50
CYP1A2 P05177 1/20 0.48
CYP2C19 P33261 1/20 0.48
PLAU P00749 1/20 0.47
STAT3 P40763 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
CSF1R P07333 2/20 0.46
LYN P07948 1/20 0.46
KIT P10721 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC2 Q92769 1/20 0.46
MAPK13 O15264 1/20 0.46
MAPK12 P53778 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7614087 0.88 KCNQ3 (0.54) KCNQ3KCNQ2MAPTSMN1; SMN2BRAF
SCHEMBL2970080 0.87 MAPT (0.65) KCNQ3KCNQ2MAPTSMN1; SMN2RAB9A
SCHEMBL7851337 0.84 MAPK14 (0.52) KCNQ3KCNQ2MAPTBRAFCYP1A2
SCHEMBL5897677 0.83 MAPK14 (0.63) BRAFCSF1RLYNMAPK14
SCHEMBL2969766 0.83 HDAC3 (0.51) MAPTSMN1; SMN2RAB9AHTTPLAU
SCHEMBL2980235 0.80 SIRT6 (0.51) MAPTSMN1; SMN2LMNAHTTNPC1
SCHEMBL2974983 0.80 PLAU (0.47) MAPTSMN1; SMN2BRAFRAB9AHTT
SCHEMBL7853049 0.80 HDAC3 (0.49) MAPTSMN1; SMN2BRAFRAB9AHTT
SCHEMBL2979404 0.79 SMN1; SMN2 (0.56) MAPTSMN1; SMN2RAB9ALMNAHTT
SCHEMBL5897239 0.79 MAPT (0.66) MAPTSMN1; SMN2RAB9ALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772432-B2 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA AB (SE) 2010-08-10 US disclosed
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA 2005-02-17 US disclosed
US-6821965-B1 IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION ASTERZENECA AB (SE) 2004-11-23 US disclosed
EP-1102743-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-05-30 EP disclosed
WO-2000007980-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors IL6, IL6ST, IL2 KCNQ3 721/4885KCNQ2 947/4885MAPT 4659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.